Literature DB >> 28211573

The cationic small molecule GW4869 is cytotoxic to high phosphatidylserine-expressing myeloma cells.

Slavica Vuckovic1,2,3, Kate Vandyke4,5, David A Rickards6, Padraig McCauley Winter6, Simon H J Brown7, Todd W Mitchell7, Jun Liu8, Jun Lu8, Philip W Askenase9, Elizabeth Yuriev10, Ben Capuano10, Paul A Ramsland11,12,13,14, Geoffrey R Hill1,15, Andrew C W Zannettino4,5, Andrew T Hutchinson6,9,12.   

Abstract

We have discovered that a small cationic molecule, GW4869, is cytotoxic to a subset of myeloma cell lines and primary myeloma plasma cells. Biochemical analysis revealed that GW4869 binds to anionic phospholipids such as phosphatidylserine - a lipid normally confined to the intracellular side of the cell membrane. However, interestingly, phosphatidylserine was expressed on the surface of all myeloma cell lines tested (n = 12) and 9/15 primary myeloma samples. Notably, the level of phosphatidylserine expression correlated well with sensitivity to GW4869. Inhibition of cell surface phosphatidylserine exposure with brefeldin A resulted in resistance to GW4869. Finally, GW4869 was shown to delay the growth of phosphatidylserine-high myeloma cells in vivo. To the best of our knowledge, this is the first example of using a small molecule to target phosphatidylserine on malignant cells. This study may provide the rationale for the development of phosphatidylserine-targeting small molecules for the treatment of surface phosphatidylserine-expressing cancers.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  GW4869; multiple myeloma; phosphatidylserine; small molecule

Mesh:

Substances:

Year:  2017        PMID: 28211573     DOI: 10.1111/bjh.14561

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   8.615


  7 in total

1.  Epithelial to mesenchymal transition influences fibroblast phenotype in colorectal cancer by altering miR-200 levels in extracellular vesicles.

Authors:  Rahul Bhome; Muhammad Emaduddin; Victoria James; Louise M House; Stephen M Thirdborough; Massimiliano Mellone; Joeri Tulkens; John N Primrose; Gareth J Thomas; Olivier De Wever; Alex H Mirnezami; A Emre Sayan
Journal:  J Extracell Vesicles       Date:  2022-05

Review 2.  Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication.

Authors:  Mathilde Mathieu; Lorena Martin-Jaular; Grégory Lavieu; Clotilde Théry
Journal:  Nat Cell Biol       Date:  2019-01-02       Impact factor: 28.824

3.  Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts.

Authors:  Sylvia Faict; Joséphine Muller; Kim De Veirman; Elke De Bruyne; Ken Maes; Louise Vrancken; Roy Heusschen; Hendrik De Raeve; Rik Schots; Karin Vanderkerken; Jo Caers; Eline Menu
Journal:  Blood Cancer J       Date:  2018-11-08       Impact factor: 11.037

4.  Cancer exosomes induce tumor innervation.

Authors:  Marianna Madeo; Paul L Colbert; Daniel W Vermeer; Christopher T Lucido; Jacob T Cain; Elisabeth G Vichaya; Aaron J Grossberg; DesiRae Muirhead; Alex P Rickel; Zhongkui Hong; Jing Zhao; Jill M Weimer; William C Spanos; John H Lee; Robert Dantzer; Paola D Vermeer
Journal:  Nat Commun       Date:  2018-10-16       Impact factor: 14.919

Review 5.  Role of Extracellular Vesicle-Based Cell-to-Cell Communication in Multiple Myeloma Progression.

Authors:  Ilaria Saltarella; Aurelia Lamanuzzi; Benedetta Apollonio; Vanessa Desantis; Giulia Bartoli; Angelo Vacca; Maria Antonia Frassanito
Journal:  Cells       Date:  2021-11-16       Impact factor: 6.600

6.  Blockade of exosome generation by GW4869 inhibits the education of M2 macrophages in prostate cancer.

Authors:  Yilin Peng; Min Zhao; Yinying Hu; Hongyan Guo; Yanyan Zhang; Yanqin Huang; Lin Zhao; Yong Chai; Zhigang Wang
Journal:  BMC Immunol       Date:  2022-08-08       Impact factor: 3.594

7.  Role of extracellular vesicles secretion in paclitaxel resistance of prostate cancer cells.

Authors:  Ashish Kumar; Pawan Kumar; Mitu Sharma; Susy Kim; Sangeeta Singh; Steven J Kridel; Gagan Deep
Journal:  Cancer Drug Resist       Date:  2022-06-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.